Amicus Therapeutics Gets FDA Approval for Pombiliti + Opfolda
By Chris Wack
Trading in shares of Amicus Therapeutics was halted at $12.88 as the Food and Drug Administration approved Pombiliti + Opfolda 65mg capsules for adults living with late-onset Pompe disease, and who aren't improving on their current enzyme replacement therapy.
The stock hit its 52-week high of $14.10 on Aug. 9, and is up 20% in the past 12 months.
Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase.
Pombiliti is a recombinant human enzyme naturally expressed with high levels of bis-Mannose 6-Phosphate, designed for increased uptake into muscle cells. Opfolda is an enzyme stabilizer designed to stabilize the enzyme in the blood.
The FDA approval was based on clinical data observed from a Phase 3 pivotal study, the only trial in late-onset Pompe disease to study ERT-experienced participants in a controlled setting.
Amicus Therapeutics will launch Pombiliti + Opfolda immediately in the U.S. The FDA previously granted Breakthrough Therapy designation for Pombiliti + Opfolda. It has also been approved for the treatment of adults with late-onset Pompe disease in the E.U. and the U.K.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 28, 2023 11:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage